Figures & data
Table 1 Summary of Phase II/III trials of PARP inhibitors
Table 2 Ongoing trials of PARP inhibitor combinations
Table 3 Grade 3–4 toxicity profiles of PARP inhibitors
Figure 1 Conceptual diagram of resistance mechanisms to PARP inhibitors.
Abbreviations: PARP, poly(ADP-ribose) polymerase; HRR, homologous recombination repair.
![Figure 1 Conceptual diagram of resistance mechanisms to PARP inhibitors.](/cms/asset/4ca02eb9-eb0a-4afc-97fe-eefa1acf282f/dott_a_12195587_f0001_c.jpg)
Figure 2 Current indications for olaparib, rucaparib, and niraparib.
Abbreviation: HRR, homologous recombination repair.
![Figure 2 Current indications for olaparib, rucaparib, and niraparib.](/cms/asset/ffd94d8e-14e5-4176-88d1-35adee49a32c/dott_a_12195587_f0002_c.jpg)
Figure 3 Current status of PARP inhibitors.
Abbreviations: PARP, poly(ADP-ribose) polymerase; HRR, homologous recombination repair; PFS, progression-free survival; OS, overall survival.
![Figure 3 Current status of PARP inhibitors.](/cms/asset/d6890265-de27-41db-9dd5-51fa7278a6fe/dott_a_12195587_f0003_c.jpg)